Use of CPG oligonucleotides in the treatment of hepatitis C virus infection

Details for Australian Patent Application No. 2003283647 (hide)

Owner Coley Pharmaceutical GmbH Coley Pharmaceutical Group, Ltd.

Inventors Davis, Heather, L.; Ahluwalia, Navneet, K.; Efler, Susan, M.; Vollmer, Jorg

Agent Davies Collison Cave

Pub. Number AU-B-2003283647

PCT Number PCT/IB2003/0055

PCT Pub. Number WO2004/039829

Priority 60/421,987 29.10.02 US

Filing date 29 October 2003

Wipo publication date 25 May 2004

Acceptance publication date 15 April 2010

International Classifications

A61K 38/21 (2006.01) Medicinal preparations containing peptides - Interferons

A61K 31/7088 (2006.01) - Compounds having three or more nucleosides or nucleotides

A61P 31/14 (2006.01) Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics

G01N 33/576 (2006.01) Investigating or analysing materials by specific methods not covered by groups - for hepatitis

Event Publications

25 March 2004 Complete Application Filed

  Priority application(s): 60/421,987 29.10.02 US

24 June 2004 Application Open to Public Inspection

  Published as AU-B-2003283647

15 April 2010 Application Accepted

  Published as AU-B-2003283647

12 August 2010 Standard Patent Sealed

24 May 2012 Application Lapsed, Refused Or Withdrawn, Patent Ceased or Expired

  This patent ceased under section 143(a), or Expired. Note that applications or patents shown as lapsed or ceased may be restored at a later date.

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2003283648-COMPOUNDS AS RADIOLIGANDS FOR THE DIAGNOSIS OF DISEASE

2003283646-THE USE OF ARYLAND HETEROARYL-SUBSTITUTED TETRAHYDROISOQUINOLINES IN THE TREATMENT OF CHRONIC AND NEUROPATHIC PAIN, MIGRAINE HEADACHES, AND URGE, STRESS AND MIXED URINARY INCONTINENCE